HDAC9 and breast carcinoma: Although treatment with AFP464 alone could be an option for patients with luminal and basal A subtype breast cancers, patients with basal B subtype or mesenchymal-like TNBC might require combined treatment with AFP464 and gene expression-modifying agents, such as HDAC inhibitors.